Clinical Core B

项目摘要/摘要 宾夕法尼亚大学佩雷尔曼学院NIA U19中心的核心B(临床核心) 医学将对实现所有项目的目标和这一多学科的其他核心至关重要 研究计划。宾夕法尼亚大学U19中心专注于解决阿尔茨海默病(AD)和 多病因痴呆的主题领域中的相关痴呆(ADRD)，如路易体(LBD)障碍 (LBD)，包括路易体痴呆(DLB)和帕金森病(PD)痴呆(PDD)。其中 ADRD、AD是AD最常见的亚型，伴有丰富的LB型共病。因此，AD与Lb和Lewis一起 轴突(LN)α-突触核蛋白(ASyn)病理(AD+aSyn)、PDD和DLB共同代表最多 常见形式的与衰老相关的痴呆。这个新的宾夕法尼亚ADRD U19中心的总体目标是 阐明AD+aSyn与单纯aSyn病理性aSyn介导的进行性神经退行性变的机制 AD(AD-aSyn)，并与LBD进行比较，作为老化和非均质积累的函数 ASyn、tau和淀粉样蛋白β(Aβ)的病理影响这些疾病的不同和不同的临床表现 精神错乱。核心B的目标是：(1)为U19招募、评估和保留患有LBD的研究参与者 项目I-IV；(2)与核心C合作，从现有和新的生物标记物/生物流体和组织收集 核心B型LBD参与者，并对他们进行纵向评估，尽可能长时间地优化 临床-病理相关性；(3)与核心A合作，教育医学界和普通 向公众介绍LBD和相关疾病，并培训下一代PD临床和翻译人员 研究人员；以及(4)与Core D合作，为宾夕法尼亚大学贡献高质量的临床和生物标记数据 集成神经退行性疾病数据库(INDD)，促进临床和生物标记物数据的共享 在宾夕法尼亚内外与新的和长期的国内、国内和国际合作者合作。

Project Summary / Abstract Core B (Clinical Core) of this NIA U19 Center at the University of Pennsylvania (Penn) Perelman School of Medicine will be crucial to accomplishing the goals of all Projects and other Cores of this multidisciplinary research program. The Penn U19 Center focuses on priorities that address Alzheimer's disease (AD) and related dementias (ADRD) in topic areas of multiple etiology dementias, such as Lewy body (LB) disorders (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease (PD) dementia (PDD). Among ADRD, AD with abundant LB co-pathology is the most common subtype of AD. Hence, AD with LB and Lewy neurite (LN) alpha-synuclein (aSyn) pathologies (AD+aSyn), PDD and DLB together represent the most common forms of aging-related dementias. The overall goals of this new Penn ADRD U19 Center are to elucidate mechanisms of pathological aSyn-mediated progressive neurodegeneration in AD+aSyn versus pure AD (AD-aSyn), and also compared with LBD, as a function of aging and the heterogeneous accumulations of aSyn, tau and amyloid β (Aβ) pathologies that influence different and variable clinical manifestations of these disorders. The aims for Core B are to: (1) recruit, assess and retain research participants with LBD for U19 Projects I-IV; (2) collaborate with Core C for biomarker/biofluid and tissue collection from existing and new Core B LBD participants, and to assess them longitudinally antemortem for as long as possible to optimize clinical-pathological correlations; (3) collaborate with Core A to educate the medical community and general public on LBD and related disorders, and to train the next generation of PD clinical and translational researchers; and (4) collaborate with Core D to contribute high-quality clinical and biomarker data to the Penn Integrated NeuroDegenerative Disease Database (INDD) and facilitate sharing of clinical and biomarker data within and outside of Penn with new and longstanding internal, national and international collaborators.